Dupixent® (dupilumab) approved by European Commission as first and only biologic medicine for children aged 6 to 11 years with severe atopic dermatitis

Joey Cohen
Medication Adherence

Daniel Sontupe
Market Access

Frank Burrell
Scientific Storytelling

Brenda Snow
Authentic Patient Voice

Liz Kane
Impactful Strategy

Matt Turner
Patient Affordability

Paul Theisen
Patient Acquisition

Pat Purcell
Meeting Engagement

Stacey Gandler
Brand Nourishment

Amy Giles
Increasing Engagement

Suma Ramadas, PhD
Medical Affairs

Bud Bilanich
Success Coach

David Linetsky
Point-of-Care Marketing

Matthew Durham
Omnidynamic Marketing